Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SI | P14410 | 1/20 | 0.34 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.34 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4685380 | 0.83 | ALDH1A1 (0.41) | HCAR2ALDH1A1MEN1NPC1KMT2A | |
| SCHEMBL271883 | 0.83 | MGAM (0.44) | ALDH1A1KMT2ACYP2D6LMNAHSD17B10 | |
| SCHEMBL27839156 | 0.82 | HCAR2 (0.36) | HCAR2ALDH1A1MEN1NPC1KMT2A | |
| SCHEMBL5200303 | 0.81 | KMT2A (0.36) | KMT2ASMN1; SMN2ALOX15EGLN1TSHR | |
| SCHEMBL1495985 | 0.80 | ALDH1A1 (0.42) | HCAR2ALDH1A1MEN1NPC1KMT2A | |
| SCHEMBL11603118 | 0.77 | MAPT (0.38) | ALOX15SLC22A6 | |
| SCHEMBL14362323 | 0.77 | ALDH1A1 (0.39) | HCAR2ALDH1A1CYP2D6SMN1; SMN2LMNA | |
| SCHEMBL1516015 | 0.77 | ALDH1A1 (0.39) | HCAR2ALDH1A1KMT2ACYP2D6LMNA | |
| SCHEMBL9127668 | 0.77 | ALDH1A1 (0.39) | HCAR2ALDH1A1CYP2D6SMN1; SMN2LMNA | |
| SCHEMBL9792742 | 0.76 | CASP1 (0.37) | SMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103534241-B | Fak inhibitor | Cancer Therapeutics CRC Pty Ltd. (AU) | 2015-11-25 | — | — | CN | disclosed |
| CN-103534241-A | Fak inhibitor | CANCER THERAPEUTICS CRC PTY LTD | 2014-01-22 | — | — | CN | disclosed |
| US-8541455-B2 | Derivatives of 2-pyridin-2-yl-pyrazol-3(2H)-one, preparation and therapeutic use thereof as HIF activators | SANOFI (FR) | 2013-09-24 | — | — | US | disclosed |
| US-20110294788-A1 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS | SANOFI (FR) | 2011-12-01 | — | — | US | disclosed |
| CN-100584844-C | Imidazole [1,2-C] pyrimidyl acetic acid derivs | ACTIMIS PHARMACEUTICALS INC | 2010-01-27 | — | — | CN | disclosed |
| CN-1938310-A | Imidazo 1,2-c pyrimidinylacetic acid derivatives | ACTIMIS PHARMACEUTICALS INC (US) | 2007-03-28 | — | — | CN | disclosed |
| EP-0188094-B1 | QUINAZOLINE DERIVATIVES AND ANTIHYPERTENSIVE PREPARATIONS CONTAINING SAME AS EFFECTIVE COMPONENTS | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1992-03-18 | — | — | EP | disclosed |
| US-4734418-A | Quinazoline compounds and antihypertensives | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1988-03-29 | — | — | US | disclosed |
| EP-0188094-A2 | Quinazoline derivatives and antihypertensive preparations containing same as effective components | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1986-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294788-A1 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS | HIF1AN, HIF1A, EGLN2 | HCAR2 608/4885ALDH1A1 1475/4885MEN1 3807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.